PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy

Paco E Bravo1, Aurélio Pinheiro, Takahiro Higuchi

  • 1Division of Nuclear Medicine, Department of Radiology, Johns Hopkins University, Baltimore, MD, USA. pbravov1@jhmi.edu

Insights

Maximal wall thickness, not outflow tract obstruction, is the key predictor of impaired microvascular function in hypertrophic cardiomyopathy (HCM). This finding impacts understanding of HCM prognosis and treatment strategies.

Area of Science:

  • Cardiology
  • Cardiovascular Imaging
  • Nuclear Cardiology

Background:

  • Obstructive hypertrophic cardiomyopathy (HCM) is associated with worse prognosis compared to non-obstructive HCM.
  • Left ventricular outflow tract gradients (LVOTGs) are elevated in obstructive HCM.
  • Microvascular function in HCM requires further investigation.

Purpose of the Study:

  • To compare PET-derived microvascular function parameters between obstructive and non-obstructive HCM.
  • To determine predictors of impaired myocardial blood flow and flow reserve in HCM patients.

Main Methods:

  • Positron Emission Tomography (PET) assessed myocardial perfusion, blood flow (MBF), and flow reserve (MFR) at rest and during dipyridamole stress.
  • Patients were categorized into non-obstructive, obstructive, and latent HCM groups based on LVOTG.
  • Echocardiography measured myocardial wall thickness and LVOTG.

Main Results:

  • Maximal wall thickness was the strongest predictor of reduced peak MBF and MFR (P < 0.0001).
  • Outflow tract obstruction (LVOTG) did not independently predict impaired flow dynamics.
  • Regional myocardial perfusion defects and reduced LVEF were more common in obstructive and non-obstructive groups during peak stress.

Conclusions:

  • Maximal wall thickness is the primary determinant of impaired dipyridamole-induced hyperemia and MFR in HCM.
  • Outflow tract obstruction is not an independent predictor of microvascular dysfunction in this cohort.
  • These findings highlight the importance of myocardial hypertrophy in HCM pathophysiology.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...